Slow Capital Inc. Purchases 10,152 Shares of CRISPR Therapeutics AG $CRSP

Key Points

• Slow Capital Inc. increased its stake in CRISPR Therapeutics AG by 15.6%, acquiring an additional 10,152 shares to own a total of 75,396 shares, valued at approximately $3.67 million.
• Institutional investors now hold 69.20% of CRISPR Therapeutics' stock, indicating strong interest from hedge funds and other investment firms.
• Analysts have mixed views on CRISPR's stock, with ten rating it as a Buy, seven as a Hold, and two as a Sell, contributing to a consensus target price of $71.50.

Slow Capital Inc. raised its stake in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 15.6% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 75,396 shares of the company's stock after purchasing an additional 10,152 shares during the quarter. Slow Capital Inc. owned approximately 0.09% of CRISPR Therapeutics worth $3,667,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently bought and sold shares of the stock. GAMMA Investing LLC grew its stake in shares of CRISPR Therapeutics by 8,146.2% in the first quarter. GAMMA Investing LLC now owns 4,288 shares of the company's stock valued at $146,000 after buying an additional 4,236 shares in the last quarter. NBC Securities Inc. grew its position in shares of CRISPR Therapeutics by 156,300.0% in the 1st quarter. NBC Securities Inc. now owns 1,564 shares of the company's stock valued at $53,000 after acquiring an additional 1,563 shares during the period. Farther Finance Advisors LLC grew its position in shares of CRISPR Therapeutics by 46.7% in the 1st quarter. Farther Finance Advisors LLC now owns 5,626 shares of the company's stock valued at $186,000 after acquiring an additional 1,792 shares during the period. Avanza Fonder AB bought a new position in shares of CRISPR Therapeutics in the 1st quarter valued at about $866,000. Finally, SG Americas Securities LLC grew its position in shares of CRISPR Therapeutics by 39.1% in the 1st quarter. SG Americas Securities LLC now owns 29,341 shares of the company's stock valued at $998,000 after acquiring an additional 8,240 shares during the period. 69.20% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts recently commented on CRSP shares. Weiss Ratings reiterated a "sell (d-)" rating on shares of CRISPR Therapeutics in a report on Saturday, September 27th. JPMorgan Chase & Co. initiated coverage on CRISPR Therapeutics in a research note on Thursday, September 18th. They set an "overweight" rating and a $70.00 target price for the company. JMP Securities reiterated a "market outperform" rating and set a $86.00 target price on shares of CRISPR Therapeutics in a research note on Friday, June 27th. Chardan Capital reaffirmed a "buy" rating and set a $82.00 price objective on shares of CRISPR Therapeutics in a research report on Tuesday, August 5th. Finally, Barclays lifted their target price on shares of CRISPR Therapeutics from $42.00 to $56.00 and gave the stock an "equal weight" rating in a report on Wednesday, August 6th. Ten equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have given a Sell rating to the company's stock. According to MarketBeat, CRISPR Therapeutics presently has a consensus rating of "Hold" and a consensus target price of $71.50.

Insiders Place Their Bets

In related news, Director Simeon George bought 989,812 shares of the company's stock in a transaction dated Wednesday, July 16th. The stock was purchased at an average price of $52.03 per share, with a total value of $51,499,918.36. Following the completion of the acquisition, the director owned 1,730,179 shares of the company's stock, valued at $90,021,213.37. The trade was a 133.69% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 4.30% of the stock is owned by insiders.

CRISPR Therapeutics Stock Performance

NASDAQ:CRSP opened at $70.19 on Tuesday. CRISPR Therapeutics AG has a fifty-two week low of $30.04 and a fifty-two week high of $73.95. The stock has a fifty day moving average price of $57.82 and a 200-day moving average price of $48.06. The company has a market cap of $6.38 billion, a price-to-earnings ratio of -12.93 and a beta of 1.84.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last issued its quarterly earnings results on Monday, August 4th. The company reported ($1.29) earnings per share for the quarter, topping analysts' consensus estimates of ($1.47) by $0.18. CRISPR Therapeutics had a negative net margin of 1,229.43% and a negative return on equity of 20.05%. The company had revenue of $0.89 million during the quarter, compared to the consensus estimate of $6.44 million. During the same quarter in the prior year, the firm posted ($1.49) EPS. The firm's quarterly revenue was up 72.5% on a year-over-year basis. Research analysts predict that CRISPR Therapeutics AG will post -5.16 EPS for the current fiscal year.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.

Want to see what other hedge funds are holding CRSP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.